Active ingredient

LBB Specialties Announces Senior Vice President for Life Sciences

Retrieved on: 
Mercredi, avril 12, 2023
University, College, Senior, Marketing, API, White House Conference on Food, Nutrition, and Health, Chromatography, MBA, Active ingredient, Univar Solutions, Biochemistry, Burns, Roquette, Growth, LBB, Management, Fine chemical, Chemistry

NORWALK, Conn., April 12, 2023 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredients distribution in North America, announced Seth Burns has joined LBB Specialties as Senior Vice President, Life Sciences.

Key Points: 
  • NORWALK, Conn., April 12, 2023 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredients distribution in North America, announced Seth Burns has joined LBB Specialties as Senior Vice President, Life Sciences.
  • In his new role, Burns will be responsible for establishing, implementing, and executing the business and commercial strategy for the Life Sciences vertical.
  • Burns brings a wealth of Life Sciences experience to LBB Specialties, including technical, sales, marketing, business, and supplier development across both distribution and manufacturing.
  • "I am thrilled to join the team at LBB Specialties to lead the Life Sciences vertical, leveraging the expertise and reputation of the organization for long-term growth in the industry," said Burns.

Edge Direct to Speak at NTEN Nonprofit Technology Conference

Retrieved on: 
Lundi, avril 3, 2023
Active ingredient, Education, Marketing, Development, Social change, CRM, Health, McWilliams, Conference, Automation, Management

BALTIMORE, April 3, 2023 /PRNewswire-PRWeb/ -- Edge Direct, a Moore company, is pleased to announce Margaret Chialastri, vice president of Development and Integrated Direct Response of Edge Direct, and Christy McWilliams, vice president of Audience Strategy of Edge Direct, will present at the 2023 NTEN Nonprofit Technology Conference (23NTC) in April.

Key Points: 
  • BALTIMORE, April 3, 2023 /PRNewswire-PRWeb/ -- Edge Direct , a Moore company, is pleased to announce Margaret Chialastri, vice president of Development and Integrated Direct Response of Edge Direct, and Christy McWilliams, vice president of Audience Strategy of Edge Direct, will present at the 2023 NTEN Nonprofit Technology Conference (23NTC) in April.
  • Chialastri brings more than 15 years of broad agency experience within the nonprofit, commercial and government sectors to this session.
  • The NTEN Conference brings together fundraising and marketing professionals who want to make the world a better place through the skillful and equitable use of technology.
  • A leading agency for nonprofits and associations, Edge Direct represents some of the most recognized nonprofit brands in the country.

Nanophase Reports Third Consecutive Year of Record Revenue for 2022

Retrieved on: 
Mercredi, mars 29, 2023
Active ingredient, Intellectual property, Loss, Advanced Materials, Q&A, Telco, API, OTCQB, GAAP, YOY, EDT, PIN, Beauty, Investment, Engineering, Webcast, Growth, CDT, Skin, Pharmaceutical industry, Cryptocurrency, Broadcasting

ROMEOVILLE, Ill., March 29, 2023 (GLOBE NEWSWIRE) -- Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — today announced financial results for the fourth quarter and fiscal year ended December 31, 2022. 

Key Points: 
  • Jess Jankowski, President and Chief Executive Officer, commented: “We have had some big wins in 2022 and so far in 2023.
  • Revenue for the full year was $37.3 million vs. $29.5 million for the same period in 2021, a 27% increase.
  • For the full year of 2022:
    Solésence revenue was $23.1 million, up 27% from $18.2 million in 2021.
  • Nanophase and Solésence Beauty Science were named in Fast Company’s World’s Most Innovative Companies for 2023, positioning us as No.

WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY

Retrieved on: 
Mercredi, mars 22, 2023
Active ingredient, Pharma, Health, AB, Fermentation, CBG, WILLOW, CDMO, TSX, API, WLLW, Industrial, M3, Technology transfer, Food, Wellness, Fine chemical, Cannabigerol

The 36 m3 scaling-up production batches required for the forthcoming qualification and registration will be completed during 2023.

Key Points: 
  • The 36 m3 scaling-up production batches required for the forthcoming qualification and registration will be completed during 2023.
  • SUANFARMA' s CIPAN manufacturing site has significant expertise as a CDMO in fermentation and purification technologies under the highest standards of quality.
  • WILLOW BIOSCIENCES is a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients using its FutureGrown™ platform.
  • "CIPAN has proven itself a highly capable manufacturing partner with the efficient scaling and production of our first ingredient, CBG.

LGM Pharma Reports Strong Revenues in First Year of CDMO Operations Along With Continued Growth in Its API Sourcing Business

Retrieved on: 
Mercredi, mars 15, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Drug development, API, Powder, CGMP, Trust, R, Active ingredient, Suppository, LGM, Investment, The central science, Tablet, ATS, Growth, Clinical trial, Fine chemical, CDMO

Demand in 2022 also remained strong for LGM Pharma’s established API Services division, with over 300 unique APIs delivered and 1700+ imports handled for clients.

Key Points: 
  • Demand in 2022 also remained strong for LGM Pharma’s established API Services division, with over 300 unique APIs delivered and 1700+ imports handled for clients.
  • The CDMO division works with multiple dosage forms including oral solid dosages, oral disintegrating tablets, powders, liquids, suspensions, semi-solids and suppositories.
  • “The strong start posted by our CDMO business reflects our company-wide commitment to supporting customer needs with quality-assured, customer-centric strategies.
  • By understanding the full life cycle of a product upfront, LGM can address their API sourcing needs in a sustainable and scalable way.

Pharmaceutical Regulatory Affairs in China Training Course (April 17-18, 2023) - ResearchAndMarkets.com

Retrieved on: 
Lundi, mars 13, 2023
Health, Pharmaceutical, University of Strathclyde, Novartis, Pharmaceutical formulation, Publication, WHO, Roche, DRA, Head, University of Basel, Biochemistry, Textbook, Editorial board, Foreign, Commonwealth and Development Office, London Organising Committee of the Olympic and Paralympic Games, Pharma, GSK plc, Active ingredient, Pharmaceutics, Allen & Hanburys, University of Manchester, Pharmaceutical industry, Chemistry, Pharmacy, Medtech

Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.

Key Points: 
  • Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.
  • Over 20 years were spent with Ciba-Geigy/CIBA/Novartis in all aspects of regulatory affairs including head of a group company DRA in Canada and for many years as Head of Pharma International regulatory affairs.
  • He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy.
  • He is published, and his publications include a textbook on International Pharmaceutical Registration, Active Pharmaceutical Ingredients and as Swiss correspondent to the Regulatory Affairs Journals Pharma and Medtech.

2 Day Pharmaceutical Regulatory Affairs in China Training Course: Maintain a Successful Pharmaceutical Marketing Authorisation in PRC, including Hong Kong, Macau and Taiwan (April 17-18, 2023)

Retrieved on: 
Samedi, mars 11, 2023
WHO, Pharma, DRA, Head, University of Strathclyde, Active ingredient, GSK plc, Editorial board, Foreign, Commonwealth and Development Office, Allen & Hanburys, Textbook, University of Basel, Pharmaceutical formulation, Pharmaceutics, London Organising Committee of the Olympic and Paralympic Games, Biochemistry, Roche, Novartis, University of Manchester, Publication, Pharmaceutical industry, Chemistry, Pharmacy, Medtech

Prior to this, she worked at F. Hoffmann-La Roche in Switzerland where she gained several years' experience in industry basics and pre-clinical research.

Key Points: 
  • Prior to this, she worked at F. Hoffmann-La Roche in Switzerland where she gained several years' experience in industry basics and pre-clinical research.
  • Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.
  • He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy.
  • Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs.

Asia Pharmaceutical Regulatory Affairs Training Course: Opportunities and Challenges to those Wishing to Work in the Region (October 11-13, 2023)

Retrieved on: 
Mercredi, mars 1, 2023
Pharmaceutics, Allen & Hanburys, Active ingredient, GSK plc, Foreign, Commonwealth and Development Office, Roche, DRA, University of Basel, Publication, Pharma, Head, WHO, London Organising Committee of the Olympic and Paralympic Games, Pharmaceutical formulation, University of Strathclyde, University of Manchester, Textbook, Biochemistry, Editorial board, Novartis, Pharmaceutical industry, Medtech, Pharmacy, Chemistry

Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.

Key Points: 
  • Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.
  • He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy.
  • He is published, and his publications include a textbook on International Pharmaceutical Registration, Active Pharmaceutical Ingredients and as Swiss correspondent to the Regulatory Affairs Journals Pharma and Medtech.
  • Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs.

Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis

Retrieved on: 
Mardi, février 28, 2023
Clinical trial, HCQ, Safety, Active ingredient, Arthritis, Quality of life, Inflammation, ASX, Disease, Hydroxychloroquine, Biomarker, Research, Function, Magnetic resonance imaging, MRI, NDA, RA, Rheumatoid arthritis, Human, Fatigue, Joint stiffness, API, Pharmacokinetics, Pharmaceutical industry, Birth control, Medical imaging, Patient, CBD, Avance, Pain

SYDNEY, Australia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has commenced a Phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients with rheumatoid arthritis (‘RA’). IHL-675A is a proprietary fixed dose combination drug comprising cannabidiol (CBD) and hydroxychloroquine (‘HCQ’).

Key Points: 
  • Incannex has commenced a Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Safety and Effect on Pain and Function of IHL-675A in Patients with Rheumatoid Arthritis.
  • The trial will assess the effect of IHL-675A on pain and function by utilising patient reported outcomes, disease scores and inflammatory biomarker analysis over a 24-week period.
  • There will be an option for trial participants to participate in an extension study following the trial.
  • This Phase 2 clinical trial follows the successful Phase 1 clinical trial whereby IHL-675A was observed to be well tolerated, with no adverse events of concern.

Asia Pharmaceutical Regulatory Affairs Training Course: Opportunities and Challenges to those Wishing to Work in the Region (October 11-13, 2023) - ResearchAndMarkets.com

Retrieved on: 
Vendredi, février 24, 2023
Pharmaceutical, Legal, Professional Services, Health, Pharmaceutics, Allen & Hanburys, Active ingredient, GSK plc, Foreign, Commonwealth and Development Office, Roche, DRA, University of Basel, Publication, Pharma, Head, WHO, London Organising Committee of the Olympic and Paralympic Games, Pharmaceutical formulation, University of Strathclyde, University of Manchester, Textbook, Biochemistry, Editorial board, Novartis, Pharmaceutical industry, Medtech, Pharmacy, Chemistry

Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.

Key Points: 
  • Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.
  • He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy.
  • He is published, and his publications include a textbook on International Pharmaceutical Registration, Active Pharmaceutical Ingredients and as Swiss correspondent to the Regulatory Affairs Journals Pharma and Medtech.
  • Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs.